$PGEN

Shah Rutul R sold $220K of PGEN

Shah Rutul R (Chief Operating Officer) sold 33,772 shares of PRECIGEN, INC. (PGEN) at $6.50 ($0.22M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shah Rutul R
Published Aug 3, 2026, 10:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 10:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

This is a disclosed open-market sale by an officer under a pre-arranged 10b5-1 plan; it is not a corporate action or new operating update.

02

Market read

Traders may note insider activity, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article provides no change in company guidance, trial results, financing, or regulatory developments, so the trading signal is mostly sentiment-based rather than fundamental.

Relevance 3/10Novelty 5/10Timing: filed 2026-08-03, transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Pre-arranged 10b5-1 sale by COO Shah Rutul R: 33,772 shares sold at $6.50 on 2026-08-03, total $219,518.

Expected impact

Likely minimal, unless traders extrapolate sentiment from insider activity.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary sales.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical and may not reflect bearish expectations; the market may overreact to the headline framing.

Key entities

  • PRECIGEN, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Shah Rutul R

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Related articles

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e